GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
MEDIVATION INC (MDVN) [hlAlert]

Rating:
Buy MDVN
up 908.98 %

MEDIVATION INC (MDVN) rated Buy with price target $30 by Morgan Joseph

Posted on: Wednesday,  Sep 7, 2011  12:25 PM ET by Morgan Joseph

Morgan Joseph rated Buy MEDIVATION INC (NASDAQ: MDVN) on 09/07/2011, when the stock price was $9.13. Since
then, MEDIVATION INC has gained 908.99% as of 01/27/2016's recent price of $92.07.
If you would have followed this Morgan Joseph's recommendation on MDVN, you would have gained 908.98% of your investment in 1603 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Morgan Joseph is committed to providing timely, objective and actionable investment advice on the companies and securities we follow. Our team of equity analysts covers a growing universe of stock issues across a broad range of industry sectors. As a middle market-focused firm, our approach is not to publish research on as many companies as possible within a number of industry sectors. Rather, our research analysts distinguish themselves by zeroing in on quality companies with growth prospects or which present special situations. These companies often lack a research following. This enables our analysts to provide insight to investors in companies that are not well understood nor fairly valued.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/7/2011 12:25 PM Buy
None
9.13 15.00
as of 12/30/2011
1 Week up  1.02 %
1 Month up  0.34 %
3 Months up  171.55 %
1 YTD up  152.65 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy